Venticort (budesonide + formoterol): Uses, Dosage & Side Effects

What it's for (Indications)

Budesonide + formoterol, an inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA) combination, is indicated for the maintenance treatment of asthma in patients 6 years of age and older.
It is also indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
This medication is designed for regular, twice-daily administration and is crucial for controlling persistent bronchoconstriction and airway inflammation associated with these conditions.
It is not indicated for the relief of acute bronchospasm; patients require a separate short-acting beta2-agonist (SABA) for acute symptom relief.
The initiation of budesonide + formoterol for asthma should be considered when asthma is not adequately controlled on an inhaled corticosteroid alone or when the severity of the disease warrants the initiation of treatment with both an inhaled corticosteroid and a LABA.

Dosage Information

Type	Guideline
Standard	For asthma, the typical recommended adult and adolescent dosage (≥12 years of age) is two inhalations twice daily, approximately 12 hours apart. Available strengths include formulations delivering 80 mcg budesonide and 4.5 mcg formoterol per actuation, or 160 mcg budesonide and 4.5 mcg formoterol per actuation. The specific strength prescribed depends on the patient's current asthma control and previous treatment. For pediatric patients (6 to <12 years of age), typically two inhalations of the 80 mcg budesonide/4.5 mcg formoterol strength twice daily. For COPD, the recommended adult dosage is generally two inhalations of the 160 mcg budesonide/4.5 mcg formoterol strength twice daily. The medication should be administered via a metered-dose inhaler, and patients should be instructed on the proper inhalation technique and to rinse their mouth with water after each dose to minimize the risk of oral candidiasis. Dosage adjustments should only be made under the supervision of a healthcare professional based on clinical response.

Type

Guideline

Standard

For asthma, the typical recommended adult and adolescent dosage (≥12 years of age) is two inhalations twice daily, approximately 12 hours apart. Available strengths include formulations delivering 80 mcg budesonide and 4.5 mcg formoterol per actuation, or 160 mcg budesonide and 4.5 mcg formoterol per actuation. The specific strength prescribed depends on the patient's current asthma control and previous treatment. For pediatric patients (6 to <12 years of age), typically two inhalations of the 80 mcg budesonide/4.5 mcg formoterol strength twice daily. For COPD, the recommended adult dosage is generally two inhalations of the 160 mcg budesonide/4.5 mcg formoterol strength twice daily. The medication should be administered via a metered-dose inhaler, and patients should be instructed on the proper inhalation technique and to rinse their mouth with water after each dose to minimize the risk of oral candidiasis. Dosage adjustments should only be made under the supervision of a healthcare professional based on clinical response.

Safety & Warnings

Common Side Effects

Common adverse reactions associated with budesonide + formoterol include nasopharyngitis, oral candidiasis (thrush), upper respiratory tract infection, headache, pharyngitis, sinusitis, influenza, back pain, and gastrointestinal upset.
Due to the formoterol component, patients may experience tremors, palpitations, or tachycardia.
Inhaled corticosteroid components can lead to local effects such as dysphonia (hoarseness) and cough.
More serious, albeit less common, adverse effects include paradoxical bronchospasm, which should be immediately treated with a rescue inhaler.
Systemic effects from budesonide can include adrenal suppression, reduction in bone mineral density, growth reduction in children, and ocular effects such as glaucoma or cataracts, especially with long-term use.
Hypersensitivity reactions, including angioedema, urticaria, and rash, may occur.
In patients with COPD, there is an increased risk of pneumonia.
Regular monitoring for these adverse effects is essential, and patients should report any new or worsening symptoms to their healthcare provider promptly.

Serious Warnings

Black Box Warning: Long-acting beta2-adrenergic agonists (LABA), such as formoterol, increase the risk of asthma-related death. Data from a large placebo-controlled U.S. study (Salmeterol Multicenter Asthma Research Trial, SMART) that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA. No study adequate to determine whether the rate of asthma-related death is increased with budesonide + formoterol has been conducted. Therefore, budesonide + formoterol should only be used in asthma as maintenance therapy if the patient's asthma is not adequately controlled on an inhaled corticosteroid (ICS) alone or if the severity of their asthma clearly warrants initiation of treatment with both an ICS and a LABA. Once asthma control is achieved and maintained, the need for continued LABA therapy should be reassessed. Available data do not suggest an increased risk of death with LABA-containing products in patients with chronic obstructive pulmonary disease (COPD).
Budesonide + formoterol is not indicated for the relief of acute bronchospasm and should not be used as a rescue therapy; a short-acting beta2-agonist must be used for acute symptoms.
Therapy should not be initiated in patients during rapidly deteriorating or acutely worsening asthma or COPD.
Sudden discontinuation of corticosteroids can be dangerous, potentially leading to adrenal insufficiency; dosage should be tapered gradually under medical supervision.
The formoterol component may produce clinically significant cardiovascular effects, including increases in pulse rate, blood pressure, and/or symptoms of cardiac arrhythmia (e.
g.
, palpitations, chest pain).
Caution is advised in patients with cardiovascular disorders, convulsive disorders, thyrotoxicosis, or diabetes mellitus.
Inhaled corticosteroids may lead to systemic effects such as hypercorticism and adrenal suppression, particularly at high doses or with prolonged use.
Patients are at increased risk of infection, including tuberculosis, fungal, bacterial, viral, or parasitic infections.
Long-term use of ICS may cause reduction in bone mineral density, and ocular effects like glaucoma and cataracts.
Paradoxical bronchospasm may occur, which can be life-threatening.
Oral candidiasis can be minimized by rinsing the mouth after inhalation.
Close monitoring is warranted for any signs of worsening disease, particularly in COPD patients for pneumonia.

How it Works (Mechanism of Action)

Budesonide + formoterol combines two distinct pharmacological agents with complementary mechanisms of action to provide comprehensive management of asthma and COPD. Budesonide is a potent synthetic corticosteroid that exerts anti-inflammatory effects primarily through binding to glucocorticoid receptors within the cell cytoplasm. This binding leads to the translocation of the receptor-steroid complex into the nucleus, where it modulates gene expression, upregulating anti-inflammatory genes and downregulating pro-inflammatory genes. This action reduces airway inflammation, decreases airway hyperresponsiveness, and diminishes the number and activity of inflammatory cells such as eosinophils, mast cells, lymphocytes, macrophages, and neutrophils. Formoterol is a long-acting beta2-adrenergic agonist (LABA). It acts by selectively stimulating beta2-adrenergic receptors located in the bronchial smooth muscle. This stimulation activates adenyl cyclase, which in turn increases intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP levels lead to the relaxation of bronchial smooth muscle, resulting in bronchodilation. Formoterol's lipophilic properties contribute to its prolonged duration of action by allowing it to partition into the lipid bilayer of the cell membrane, from which it can then slowly interact with the beta2-receptors. The synergistic combination of an ICS and LABA addresses both the inflammatory and bronchoconstrictive aspects of respiratory diseases, leading to improved lung function and reduced exacerbations.